ClouDr Group Limited (9955) AI Stock Analysis

• Market Cap: HK$643.44M
• Dividend Yield: N/A
• Average Volume (3M): 1.09M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.03
• Revenue Growth: -43.86%
• EPS Growth: -217.25%
• Country: HK
• Employees: 1,218
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): -1.01
• Shares Outstanding: 645,718,800
• 10 Day Avg. Volume: 899,970
• 30 Day Avg. Volume: 1,090,236
• PEG Ratio: -0.03
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.19
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: HK$1.50 ▲(50.00% Upside)

The overall stock score is primarily impacted by the company's financial performance challenges, including persistent net losses and reliance on external financing. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics reflect ongoing profitability issues. The lack of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product adoption, positioning ClouDr for potential long-term success.

Leverage Management

Improved leverage management enhances financial stability and reduces risk, providing a stronger foundation for future growth.

Gross Profit Margin Stability

Stable gross profit margins reflect effective cost control, supporting sustainable operations and potential profitability improvements.

Negative Factors

Profitability Challenges

Ongoing profitability issues and negative cash flow highlight financial instability, posing risks to long-term viability and growth.

Negative Free Cash Flow

Consistently negative free cash flow indicates reliance on external financing, which may limit strategic flexibility and increase financial risk.

Operational Challenges

Negative operational margins suggest inefficiencies, potentially hindering ClouDr's ability to achieve sustainable profitability.

ClouDr Group Limited Business Overview & Revenue Model

Company Description

ClouDr Group Limited, an investment holding company, provides supplies and software as a service (SaaS) to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for chronic condition management. It distributes hospital supplies, which include medical devices, such as blood glucose meters and vital sign monitors, glucose testing strips, and OTC and prescription drugs; and hospital and pharmacy SaaS and digital marketing services to pharmaceutical companies. The company also provides real time consultation, digital condition tracking, and online prescription and ordering services. ClouDr Group Limited was founded in 2014 and is headquartered in Hangzhou, China.

How the Company Makes Money

ClouDr Group Limited generates revenue through multiple key streams, including subscription fees for its software-as-a-service (SaaS) products, which provide clients with access to cloud-based applications and services on a recurring basis. Additionally, the company earns income from consulting services that assist businesses in migrating to cloud solutions and optimizing their existing cloud infrastructure. Revenue is also derived from partnerships with other technology firms, allowing ClouDr to integrate its services into broader technology ecosystems. Furthermore, strategic collaborations with enterprises seeking customized cloud solutions can result in significant project-based revenue, contributing to the company's overall earnings.

ClouDr Group Limited Financial Statement Overview

Summary

ClouDr Group Limited is experiencing growth in revenue, but profitability remains a challenge with persistent net losses. Improvements in balance sheet metrics such as leverage and equity ratio are positive signs, yet historical negative equity and high liabilities are concerning. The company’s cash flow situation is precarious, relying heavily on external financing, which could impact future liquidity. Overall, while there are positive signs of growth and improved leverage, profitability and cash flow generation remain key areas of concern.

Income Statement

ClouDr Group Limited shows a consistent increase in revenue over the years, with a significant jump from 2020 to 2021. However, the company is still operating at a loss, with net losses increasing over time. The gross profit margin has remained stable, indicating efficient cost management. The negative EBIT and EBITDA margins highlight ongoing operational challenges, and the declining net income margin raises concerns about profitability in the near term.

Balance Sheet

The company's debt-to-equity ratio has improved over time, suggesting better leverage management. However, the negative stockholders' equity in earlier years indicates historical financial difficulties. The equity ratio has improved, reflecting better asset management. Despite positive trends, the company's past negative equity and high liabilities pose risks.

Cash Flow

Despite generating negative free cash flow consistently, ClouDr Group Limited managed to improve operating cash flow over recent years. The operating cash flow to net income ratio indicates that the company is still struggling with cash generation relative to its income losses. The reliance on financing activities for cash sustenance could pose liquidity risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.26B	3.49B	3.69B	2.99B	1.76B	839.12M
Gross Profit	755.69M	861.67M	909.38M	792.10M	570.02M	232.76M
EBITDA	-764.00M	-372.34M	-208.37M	-1.58B	-4.06B	-2.86B
Net Income	-949.68M	-516.41M	-323.06M	-1.69B	-4.14B	-2.87B
Balance Sheet
Total Assets	2.15B	2.84B	2.95B	2.83B	2.51B	1.69B
Cash, Cash Equivalents and Short-Term Investments	445.29M	525.84M	595.10M	723.17M	1.12B	981.42M
Total Debt	558.23M	581.24M	469.69M	228.67M	9.03B	358.62M
Total Liabilities	1.33B	1.41B	1.18B	953.05M	9.66B	5.08B
Stockholders Equity	962.37M	1.45B	1.83B	1.85B	-7.14B	-3.36B
Cash Flow
Free Cash Flow	-24.36M	-225.19M	-263.46M	-809.87M	-755.02M	-478.99M
Operating Cash Flow	61.47M	-148.39M	-140.43M	-642.63M	-666.33M	-438.46M
Investing Cash Flow	40.20M	66.87M	-38.34M	-744.94M	-155.50M	-160.20M
Financing Cash Flow	7.56M	147.99M	171.81M	503.55M	1.02B	918.41M

ClouDr Group Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 1.01, below the 50-day MA of 1.08, and below the 200-day MA of 1.22, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 36.64 is Neutral, neither overbought nor oversold. The STOCH value of 52.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9955.

ClouDr Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2192	74 Outperform	HK$8.75B	24.83	6.77%	2.72%	29.81%	10.40%
1931	62 Neutral	HK$3.78B	20.09	5.07%	3.81%	0.33%	-44.28%
2289	60 Neutral	HK$786.24M	15.08	8.12%	8.03%	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9955	40 Underperform	HK$643.44M	-0.58	-69.05%	―	-43.86%	-217.25%

ClouDr Group Limited Corporate Events

ClouDr Group Names HR Chief Hu Yue as Executive Director and Nomination Committee Member

ClouDr Group Limited has appointed Hu Yue, the group’s long-serving vice president and head of human resources, as an executive director and member of its nomination committee, effective 27 December 2025. Hu, a seasoned HR executive with prior leadership roles at Johnson & Johnson in multiple international locations and academic experience at Shanghai University, will serve under a one-year service agreement without additional director remuneration, and will be subject to retirement by rotation and re-election under the company’s governance rules, underscoring a continuity-focused refresh of the board’s composition and nomination oversight.

The most recent analyst rating on (HK:9955) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.

ClouDr Group Sets Out Board and Committee Structure

ClouDr Group Limited announced the current composition of its board of directors, comprising executive directors Kuang Ming, who serves as chairman and chief executive officer, and Hu Yue, alongside independent non-executive directors Hong Weili, Zhang Saiyin and Ang Khai Meng. The company also detailed the structure of its three key board committees—Audit, Remuneration and Nomination—including the designation of Zhang Saiyin as chair of the Audit Committee, Hong Weili as chair of the Remuneration Committee and Kuang Ming as chair of the Nomination Committee, clarifying governance responsibilities and signaling an emphasis on defined oversight and accountability within its corporate structure.

The most recent analyst rating on (HK:9955) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.

ClouDr Group Partners with JD Health to Enhance Online Healthcare Services

ClouDr Group Limited has entered a service cooperation agreement with JD Health to expand online sales and service channels for its products, including Remifemin. This collaboration leverages JD Health’s extensive platform resources and ClouDr’s expertise in chronic disease management, aiming to promote high-quality, cost-effective medications and improve patient experiences.

The most recent analyst rating on (HK:9955) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.

ClouDr Group Limited Terminates Transactions and Pursues Legal Action

ClouDr Group Limited announced the termination of certain discloseable transactions due to a breach of contract by Ms. Zhu, who failed to fulfill her payment obligations. The company has entered into a new agreement for the disposal of assets and is pursuing legal action to seek compensation for the breach, which contributed to a significant net loss during the reporting period.

The most recent analyst rating on (HK:9955) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on ClouDr Group Limited stock, see the HK:9955 Stock Forecast page.